Supplementary Figure Legends

Supplementary Figure 1: Silencing GRP78 combined with chemotherapeutics decreases viability in pancreatic cancer cell lines. (A) S2-VP10 cells transfected with siGRP78 and treated with 100 nM gemcitabine, 50 nM paclitaxel, or 5 μ M 5-fluorouracil for 24 and 48 hours resulted in decreased viability compared to treatment or silencing alone. (B) Su.86.86 cells transfected with siGRP78 and treated with 400 nM gemcitabine, 50 nM paclitaxel, or 5 μ M 5-fluorouracil for 24 and 48 hours resulted in decreased viability compared to treatment or silencing alone. (B) Su.86.86 cells fluorouracil for 24 and 48 hours resulted in decreased viability compared to treatment or silencing alone.

Supplementary Figure 2: Silencing GRP78 combined with gemcitabine results in more cell death. (A) Quantitation of cleaved caspase 3 staining after MIA PaCa-2 cells were transfected with siGRP78 and treated with 400 nM gemcitabine 24 hours. (B). S2-VP10 cells transfected with non-silencing siRNA (NS) (B-I), 100 nM gemcitabine (B-II), siGRP78 (B-III), or siGRP78 + gemcitabine (B-IV) for 24 hours, and stained with cleaved caspase 3 for apoptosis, and the respective quantitation.

Supplementary Figure 3: Verapamil combined with chemotherapeutic compounds decreases cell viability in pancreatic cancer cells. MIA PaCa-2 cells were treated with 5 μ M 5-FU and 100 μ M verapamil for 24 hours to determine cell viability. S2-VP10 cells were treated with 100 μ M verapamil and either 100 nM gemcitabine, 50 nm paclitaxel, or 5 μ M 5-FU for 24 hours to determine cell viability.

Supplementary Figure 4: Sp1 is required for ER homeostasis and affects chemoresistance in pancreatic cancer cells, similarly to GRP78. S2-VP10 cells transfected with siSp1 and treated with 100 nM gemcitabine, 50 nM paclitaxel, or 5 µM 5-fluorouracil for 24

and 48 hours resulted in decreased viability compared to treatment or silencing alone (A). (B) Quantitation of cleaved caspase 3 staining after MIA PaCa-2 cells were transfected with siSp1 and treated with 400 nM gemcitabine 24 hours. (C). S2-VP10 cells transfected with non-silencing siRNA (NS) (C-I), 100 nM gemcitabine (C-II), siSp1 (C-III), or siSp1 + gemcitabine (C-IV) for 24 hours, and stained with cleaved caspase 3 for apoptosis, and the respective quantitation.

Supplementary Figure 5: Mithramycin treatment decreases SP1 and GRP78 expression *in vivo*


Immunohistochemistry with SP1 and GRP78 on subcutaneous tumor implantation: (I) Control (II) Gemcitabine 50 mg/kg (III) Mithramycin 0.3 mg/kg (IV) Mithramycin 0.3 mg/kg + Gemcitabine 50 mg/kg (V) Mithramycin 0.6 mg/kg (VI) Mithramycin 0.6 mg/kg + Gemcitabine 50 mg/kg.


Supplementary Figure 6: Evidence of silencing

(A) GRP78 (siG) was silenced for 24 and 48 hours in MIA PaCa-2 and S2-VP10 cells and compared with non-silenced scrambled control (NS). (B) SP1 (siS) was silenced for 24 and 48 hours in MIA PaCa-2 cells and for 24 hours in S2-VP10 cells and compared with NS.

А

В





Cell viability (normalized to control)

1.0

0.5


0.0


-sn


Paclitaxel + siGRP78


siGRP78-

Paclitaxel-











В


Relative cleaved caspase 3/cells




Cleaved caspase 3 - 75 um







В




75 um **Cleaved caspase 3**

+ siSp1

+ siSp1







A GRP78 silencing

MIA PaCA-2






S2-VP10



B SP1 silencing

MIA PaCA-2



S2-VP10

